Magenta Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Dianthus Therapeutics

23/03/2023 14:14

* Magenta Therapeutics Inc  MGTA.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was for a
loss of 27 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Magenta Therapeutics Inc's reported EPS for the quarter
was a
loss of 34 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Magenta Therapeutics Inc shares had risen by 89.9% this
quarter.
    * The company reported a quarterly loss of $20.18 million.
    * Wall Street's median 12-month price target for Magenta
Therapeutics Inc is $2.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 23 at 02:14 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.27          -0.34          Missed
 Sep. 30 2022      -0.30          -0.27          Beat
 Jun. 30 2022      -0.33          -0.29          Beat
 Mar. 31 2022      -0.31          -0.39          Missed